Aspen confirms Non-binding Term Sheet on manufacture and sale of an Aspen branded COVID-19 vaccine throughout Africa

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen”)


ASPEN CONFIRMS NON-BINDING TERM SHEET ON MANUFACTURE AND SALE OF AN ASPEN BRANDED
COVID-19 VACCINE THROUGHOUT AFRICA AND WITHDRAWAL OF CAUTIONARY


With reference to the cautionary announcement dated 29 November 2021, Aspen is pleased to confirm
that one of its wholly owned South African subsidiaries, Aspen SA Operations (Pty) Limited (“Aspen SA”),
has confirmed a non-binding term sheet with Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV,
two of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Johnson & Johnson”), that will form
the basis for negotiation of a definitive agreement on the manufacture and sale of an Aspen branded
COVID-19 vaccine throughout Africa. That agreement would expand the existing technical transfer and
manufacturing agreements between the parties to grant Aspen SA the rights to:

(i)     manufacture finished SARS-CoV-2 COVID-19 vaccine product from drug substance supplied by
        Johnson & Johnson; and
(ii)    sell the finished form vaccine under Aspen branding to public sector markets in Africa through
        transactions with designated multilateral organisations and with national governments of member
        states of the African Union.

In addition, Johnson & Johnson would grant Aspen a license to the enabling intellectual property for this
purpose. Aspen SA plans to launch this vaccine under the brand name “Aspenovax”.

The term of the grant of rights and supply of drug substance, subject to the signing of the definitive
agreement, would be until 31 December 2026. The non-binding term sheet contemplates a good faith
undertaking between the parties to discuss the expansion of the agreement to include any new versions of
the drug substance, such as those developed for new variants or as a different formulation for
administration as a booster, and the applicable terms thereof.

Following the above confirmation, shareholders are advised that caution is no longer required to be
exercised when dealing in the Company’s securities.

A media broadcast webinar to further discuss this matter has been scheduled to start at 15:30 (SAST) today,
30 November 2021. The details for this webinar are as follows:

Webinar ID: 990 9930 8622 | Passcode: 104435 | Webinar link:
https://aspenpharma.zoom.us/j/99099308622?pwd=SEJwYnQyYkZYYTB2R290R1hKRkpxdz09
Q&As limited to questions posted via the webinar link.

Durban
30 November 2021

Sponsor
Investec Bank Limited

Date: 30-11-2021 02:00:00

Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.